| Document |
Document Title |
|
WO/2012/059803 |
The present invention relates to the process for the preparation of estradiol valerate (I) which involves isolation of crystalline estradiol divalerate (III) by crystallization from an alcoholic solvent.
|
|
WO/2012/037261 |
Disclosed herein are 6-substituted 13-demethyl- estradiol derivatives as selective ERβ agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.
|
|
WO/2012/032529 |
The present invention provides methods for 1, 2-asymmetric reduction of other compounds wherein 1,2- trans diol is present. In particular the present invention discloses preparation of 17β-Estriol and its derivatives having substantiall...
|
|
WO/2012/013816 |
The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
|
|
WO/2012/011106 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2011/156631 |
The invention provides methods for extracting carbon-based molecules of interest produced by host cells cultured in a biphasic system. Methods and apparatus for extracting a carbon-based molecule from a host cell both in the presence of ...
|
|
WO/2011/138460 |
The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.
|
|
WO/2011/127232 |
The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds ...
|
|
WO/2011/127232 |
The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds ...
|
|
WO/2011/114220 |
Isolated compounds from adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also prov...
|
|
WO/2011/108661 |
Disclosed is a method for producing a silylenol ether compound, which is simple, has broad utility, and has a low environmental load (produces little waste). Specifically disclosed is a method for producing a silylenol ether compound (3)...
|
|
WO/2011/098439 |
The invention relates to a process for the preparation of a compound of formula (I): wherein R1 and R2 are as defined in the description, by reaction of a compound of formula (II) with a base. Compound (I) is an intermediate useful in th...
|
|
WO/2011/098439 |
The invention relates to a process for the preparation of a compound of formula (I): wherein R1 and R2 are as defined in the description, by reaction of a compound of formula (II) with a base. Compound (I) is an intermediate useful in th...
|
|
WO/2011/066542 |
Disclosed are compounds of the formula (I): where in R1, R2, R3 and R4 are independent l y hydrogen, C1 -C6 alkyl, halo, a sulfate, a glucuronide, -OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, N ( CH2 ) n; a phospha...
|
|
WO/2011/066542 |
Disclosed are compounds of the formula (I): where in R1, R2, R3 and R4 are independent l y hydrogen, C1 -C6 alkyl, halo, a sulfate, a glucuronide, -OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, N ( CH2 ) n; a phospha...
|
|
WO/2011/009529 |
The invention relates to a 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11methylene
oxyalkylene aryl derivative of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereo...
|
|
WO/2011/009529 |
The invention relates to a 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11methylene
oxyalkylene aryl derivative of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereo...
|
|
WO/2010/096928 |
Methods and devices for liquid-liquid extraction using digital microfluidic arrays are provided. A polar droplet is transported to a separation region containing a substantially non-polar solvent, where non-polar impurities may be extrac...
|
|
WO/2010/076811 |
The present invention relates to an efficient and cost-effective process for the preparation of 6- methylenandrost-1,4-diene-3,17-dione (exemestane) by dehydrogenation of 6-methylenandrost-4- ene-3,17-dione using an dehydrogenating agent...
|
|
WO/2010/043404 |
The invention relates to a compound of formula (1) wherein R1 represents hydrogen or an acetyl group and R2 represents a methyl, acetyl, or benzyl group, to its preparation, and to its use in the preparation of fulvestrant.
|
|
WO/2010/043506 |
Method for preparing 2-alkoxy and 2-aryloxyestrogen compounds, and the intermediate compounds prepared during the use of this method, which intermediate compounds are useful intermediates in the preparation of certain physiologically act...
|
|
WO/2009/135449 |
The invention relates to novel ligands of the estrogen receptors α and β of general formula (II), which are useful as active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, ...
|
|
WO/2009/137337 |
A process for forming one or the other of a 17-α-aryl or 17-β-aryl steroidal compound in diastereo excess is disclosed. The process utilizes a 17-keto steroid to form a Δ16-17-aryl-steroid compound or a 17-β-hydroxy-17-α-aryl steroi...
|
|
WO/2009/120678 |
Steroids are well known, medicinal relevant, chemical entities. There are numerous steroids which have fully or partially reduced 1A' rings. These fully or partially reduced 1A' rings have been reduced in the past through Birch and other...
|
|
WO/2009/120678 |
Steroids are well known, medicinal relevant, chemical entities. There are numerous steroids which have fully or partially reduced 1A' rings. These fully or partially reduced 1A' rings have been reduced in the past through Birch and other...
|
|
WO/2009/115060 |
5-Fluoro-3α,17β-dihydroxy-5α-androstan-6-one IV and the method of its production are described. The synthesis consists of partial hydrolyses of 5-fluoro-6-oxo-5α-androstan-3β,17β-diyl diacetate with mild alkaline agent to 5-fluoro-...
|
|
WO/2009/093262 |
The present invention discloses modified process for preparing aromatase inhibitor Exemestane involving suitable oxidizing agents in suitable solvents.
|
|
WO/2009/093262 |
The present invention discloses modified process for preparing aromatase inhibitor Exemestane involving suitable oxidizing agents in suitable solvents.
|
|
WO/2009/077454 |
6-alkylidenandrost-1, 4-dien-3-ones of general formula (I), wherein R is H o alkyl; R1 y R2, independently of one another, represent H, OR3, OC(=O)R4 or O-(GPH), wherein R3 is H; C1-C6 alkyl or aryl; R4 is H or C1-C6 alkyl,; and GPH is a...
|
|
WO/2009/059765 |
The present invention describes a process for the preparation of drospirenone (I) using androstendione as a starting material. In particular, androstendione protected on carbonyl group in position 3 as an enol-ether is functionalized in ...
|
|
WO/2009/059765 |
The present invention describes a process for the preparation of drospirenone (I) using androstendione as a starting material. In particular, androstendione protected on carbonyl group in position 3 as an enol-ether is functionalized in ...
|
|
WO/2009/053008 |
The present invention relates to 11β-fluoro-3-acetoxyestra-3,5-diene-17-on as suitable intermediate preparation for the production of 11-fluoro-sbustituted steroids and to the method for the production thereof. For this purpose, 11α-hy...
|
|
WO/2009/054725 |
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...
|
|
WO/2009/054725 |
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...
|
|
WO/2009/033499 |
The present invention relates to a total synthesis of desogestrel and derivatives thereof, and to intermediate compounds of this synthesis.
|
|
WO/2009/034398 |
The invention relates to a novel process for the synthesis of 6-hydroxymethyl-l,4- androstadien-3,17-dione which means dehydrogenating 6-hydroxymethyl-4-androsten- 3,17-dione in the presence of a biocatalyst.
|
|
WO/2009/022477 |
[PROBLEMS] To provide a polymer wherein a biologically active substance is distributed uniformly at a high density. [MEANS FOR SOLVING PROBLEMS] The problems can be solved by selecting and using polynorbornene as the polymer.
|
|
WO/2009/013310 |
A process is described for the industrial scale preparation of 7α-[9-(4,4,5,5,5- 5 pentafluorothiopentyI)nonyl]estra-1,3,5(10)-triene-3,17β-di
ol, a precursor of steroids with hormonal activity which include Fulvestrant.
|
|
WO/2009/013310 |
A process is described for the industrial scale preparation of 7α-[9-(4,4,5,5,5- 5 pentafluorothiopentyI)nonyl]estra-1,3,5(10)-triene-3,17β-di
ol, a precursor of steroids with hormonal activity which include Fulvestrant.
|
|
WO/2009/007454 |
The invention refers to 8β-substituted estra-1,3,5(10)-triene derivatives of general formula (I), their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates...
|
|
WO/2009/007454 |
The invention refers to 8β-substituted estra-1,3,5(10)-triene derivatives of general formula (I), their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates...
|
|
WO/2008/157635 |
Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
|
|
WO/2008/157635 |
Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
|
|
WO/2008/145318 |
The invention relates to a method for producing 17α-acetoxy-6-methylenepregn-4-ene-3,20-dione (4) as an intermediate preparation as well as methods for producing medroxyprogesterone acetate (1) (17α-acetoxy-6α-methylpregn-4-ene-3,20-d...
|
|
WO/2008/145318 |
The invention relates to a method for producing 17α-acetoxy-6-methylenepregn-4-ene-3,20-dione (4) as an intermediate preparation as well as methods for producing medroxyprogesterone acetate (1) (17α-acetoxy-6α-methylpregn-4-ene-3,20-d...
|
|
WO/2008/137048 |
A process of making an aromatase inhibitor of formula (I) : wherein each of R1, R2, R3, and R4, independently, is hydrogen, halogen, or C1-C6 alkyl, comprising reacting a compound of formula (II) : with an acid in the presence of a suita...
|
|
WO/2008/134668 |
Disclosed herein are heat-labile prodrugs, their preparation and uses.
|
|
WO/2008/134668 |
Disclosed herein are heat-labile prodrugs, their preparation and uses.
|
|
WO/2008/067450 |
A compound having the structure : wherein R1, R2, R3, R4, R5, R6, R7 and R9 are independently hydrogen, C1 to C6 alkyl or substituted alkyl, halogen, sulfate or glucuronide moieties; the ---- symbol represents either a single or a double...
|
|
WO/2008/063128 |
Steroid compounds having increased resistance against metabolism and increased water solubilit y are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the trea...
|
